pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.53k
3.53k
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9099X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
13057F | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | ankylosing spondylitis | Initial treatment with the subcutaneous form where a concurrent PBS authority application for the intravenously (IV) administered formulation is being made | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12090H | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment in a patient weighing less than 30 kg | 14084 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11207W | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
12625L | upadacitinib | Rinvoq | Tablet 15 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,531 | 2,025 | JANUARY |
11742B | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14150 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13216N | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13216N | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |
13216N | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | 11523 | true | STREAMLINED | Any | 3,531 | 2,025 | JANUARY |